Lysosomal phospholipase A2 inhibition robustly correlates with drugs causing phospholipidosis [51], whereas the enzyme acid sphingomyelinase has been investigated as a potential target for antidepressant action [52]. Here, PLA2G15 is linked to lysosomal storage disease.